Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.01
MSLI's Cash-to-Debt is ranked lower than
98% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. MSLI: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
MSLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 3.85 Max: No Debt
Current: 0.01
Equity-to-Asset 0.54
MSLI's Equity-to-Asset is ranked lower than
64% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MSLI: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
MSLI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.63 Max: 0.94
Current: 0.54
0.18
0.94
Piotroski F-Score: 5
Altman Z-Score: 0.61
Beneish M-Score: -2.24
WACC vs ROIC
12.21%
-1.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -1.06
MSLI's Operating Margin % is ranked lower than
74% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. MSLI: -1.06 )
Ranked among companies with meaningful Operating Margin % only.
MSLI' s Operating Margin % Range Over the Past 10 Years
Min: -1112.12  Med: -15.67 Max: 19.4
Current: -1.06
-1112.12
19.4
Net Margin % -12.10
MSLI's Net Margin % is ranked lower than
78% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. MSLI: -12.10 )
Ranked among companies with meaningful Net Margin % only.
MSLI' s Net Margin % Range Over the Past 10 Years
Min: -1787.71  Med: -30.83 Max: 17.19
Current: -12.1
-1787.71
17.19
ROE % -6.50
MSLI's ROE % is ranked lower than
74% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MSLI: -6.50 )
Ranked among companies with meaningful ROE % only.
MSLI' s ROE % Range Over the Past 10 Years
Min: -90.89  Med: -16.19 Max: 5.02
Current: -6.5
-90.89
5.02
ROA % -3.42
MSLI's ROA % is ranked lower than
73% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MSLI: -3.42 )
Ranked among companies with meaningful ROA % only.
MSLI' s ROA % Range Over the Past 10 Years
Min: -49.48  Med: -12.42 Max: 4.57
Current: -3.42
-49.48
4.57
ROC (Joel Greenblatt) % -16.63
MSLI's ROC (Joel Greenblatt) % is ranked lower than
75% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. MSLI: -16.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MSLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -627.84  Med: -115.82 Max: 92.73
Current: -16.63
-627.84
92.73
3-Year Revenue Growth Rate -1.40
MSLI's 3-Year Revenue Growth Rate is ranked lower than
72% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. MSLI: -1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MSLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.4 Max: 85.1
Current: -1.4
0
85.1
3-Year EBITDA Growth Rate -12.10
MSLI's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. MSLI: -12.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MSLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21.8  Med: 9.3 Max: 62.2
Current: -12.1
-21.8
62.2
3-Year EPS without NRI Growth Rate 21.60
MSLI's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. MSLI: 21.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MSLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -85.1  Med: -2.9 Max: 138.1
Current: 21.6
-85.1
138.1
GuruFocus has detected 4 Warning Signs with Merus Labs International Inc $MSLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MSLI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:OTCPK:CMMDF, OTCPK:ELTP, NAS:ADMP, OTCPK:ZOMHF, NAS:SMMT, OTCPK:CURR, NAS:NEOS, OTCPK:OGRMF, NAS:STDY, NAS:CPIX, NAS:AGRX, OTCPK:CPHRF, OTCPK:GRMD, OTCPK:OWCP, OTCPK:ICCLF, OTCPK:EMMBF, NAS:ARLZ, OTCPK:BIOYF, NAS:GALT, NAS:MEIP » details
Traded in other countries:MSL.Canada, 9ML.Germany,
Headquarter Location:Canada
Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products.

Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Ratios

vs
industry
vs
history
Forward PE Ratio 29.67
MSLI's Forward PE Ratio is ranked lower than
78% of the 68 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.46 vs. MSLI: 29.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 19.29
MSLI's Price-to-Owner-Earnings is ranked higher than
72% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. MSLI: 19.29 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MSLI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.12  Med: 12.39 Max: 282.5
Current: 19.29
1.12
282.5
PB Ratio 1.02
MSLI's PB Ratio is ranked higher than
88% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. MSLI: 1.02 )
Ranked among companies with meaningful PB Ratio only.
MSLI' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 0.79 Max: 2.63
Current: 1.02
0.29
2.63
PS Ratio 1.84
MSLI's PS Ratio is ranked higher than
65% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. MSLI: 1.84 )
Ranked among companies with meaningful PS Ratio only.
MSLI' s PS Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.87 Max: 53.85
Current: 1.84
0.88
53.85
Price-to-Free-Cash-Flow 12.06
MSLI's Price-to-Free-Cash-Flow is ranked higher than
78% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.35 vs. MSLI: 12.06 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MSLI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.28  Med: 7.06 Max: 218.75
Current: 12.06
1.28
218.75
Price-to-Operating-Cash-Flow 11.23
MSLI's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. MSLI: 11.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MSLI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.26  Med: 6.26 Max: 50
Current: 11.23
1.26
50
EV-to-EBITDA 9.82
MSLI's EV-to-EBITDA is ranked higher than
80% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.55 vs. MSLI: 9.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
MSLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.7  Med: 1.25 Max: 27.1
Current: 9.82
-155.7
27.1
Current Ratio 0.80
MSLI's Current Ratio is ranked lower than
93% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MSLI: 0.80 )
Ranked among companies with meaningful Current Ratio only.
MSLI' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.41 Max: 14.42
Current: 0.8
0.38
14.42
Quick Ratio 0.54
MSLI's Quick Ratio is ranked lower than
93% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MSLI: 0.54 )
Ranked among companies with meaningful Quick Ratio only.
MSLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.31  Med: 2.18 Max: 14.42
Current: 0.54
0.31
14.42
Days Inventory 126.46
MSLI's Days Inventory is ranked lower than
55% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. MSLI: 126.46 )
Ranked among companies with meaningful Days Inventory only.
MSLI' s Days Inventory Range Over the Past 10 Years
Min: 118.87  Med: 227.84 Max: 458.88
Current: 126.46
118.87
458.88
Days Sales Outstanding 99.91
MSLI's Days Sales Outstanding is ranked lower than
68% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. MSLI: 99.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.61  Med: 109.54 Max: 1249.47
Current: 99.91
3.61
1249.47

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -45.00
MSLI's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. MSLI: -45.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MSLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -116.3  Med: -28.3 Max: 25.8
Current: -45
-116.3
25.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.83
MSLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
90% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MSLI: 0.83 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MSLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.15  Med: 0.87 Max: 4.05
Current: 0.83
0.15
4.05
Price-to-Median-PS-Value 0.64
MSLI's Price-to-Median-PS-Value is ranked higher than
85% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. MSLI: 0.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MSLI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.74 Max: 17.36
Current: 0.64
0.02
17.36
Earnings Yield (Greenblatt) % -1.21
MSLI's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MSLI: -1.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MSLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1570.6  Med: -0.7 Max: 5232.3
Current: -1.21
-1570.6
5232.3

More Statistics

Revenue (TTM) (Mil) $79.09
EPS (TTM) $ -0.08
Beta2.29
Short Percentage of Float4.07%
52-Week Range $0.70 - 1.33
Shares Outstanding (Mil)117.36

Analyst Estimate

Sep17 Sep18 Sep19 Sep20
Revenue (Mil $) 83 87 89 92
EPS ($) -0.02 0.04 0.07 0.04
EPS without NRI ($) -0.02 0.04 0.07 0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MSLI

Headlines

Articles On GuruFocus.com
Merus Labs International Inc. files Management Information Circular for Proposed Acquisition by Norg Jun 05 2017 
Merus Labs International Inc. Obtains Interim Order for Plan of Arrangement Jun 01 2017 
Merus Labs Reports Fiscal Q2 2017 Results May 11 2017 
Merus Labs and Norgine Enter into a Definitive Arrangement Agreement May 11 2017 
Merus Labs Announces Key Milestone for Sintrom® Profit Enhancing Initiative May 04 2017 
Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Oct 05 2015 
Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc. Jun 22 2015 
Merus Labs International: A Pharma Stock With Growth Potential Mar 30 2015 
Merus Labs International Inc. Announces Normal Course Issuer Bid Nov 17 2014 

More From Other Websites
Merus Labs International Inc. Mails Letter to Shareholders with Reminder to Vote FOR the Proposed... Jun 27 2017
Merus Labs International Inc. files Management Information Circular for Proposed Acquisition by... Jun 05 2017
Merus Labs International Inc. Obtains Interim Order for Plan of Arrangement Jun 01 2017
Merus Labs International, Inc. :MSLI-US: Earnings Analysis: Q2, 2017 By the Numbers : May 26, 2017 May 26 2017
Merus Labs Shares Spike 50% on Acquisition May 11 2017
Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers May 11 2017
Merus Labs reports 2Q loss May 11 2017
Merus Labs and Norgine Enter into a Definitive Arrangement Agreement May 11 2017
Merus Labs Reports Fiscal Q2 2017 Results May 11 2017
Merus Labs Announces Key Milestone for Sintrom® Profit Enhancing Initiative May 04 2017
Merus Labs International, Inc. :MSLI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 16, 2017 Mar 16 2017
Merus Labs Announces Changes to Stock Option Plan to Address ISS Recommendation Mar 13 2017
Merus Labs Responds to Reuters News Article Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}